Top Markets
#1 Siren Siren +34.73%
#2 Wiki Cat Wiki Cat +30.30%
#3 Ribbita by Virtuals Ribbita by Virtuals +19.62%
#4 Bitway Bitway +19.40%
#5 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +17.45%
#6 PulseChain PulseChain +16.92%
#7 TRIA TRIA +16.78%
#8 Velvet Velvet +16.02%
#9 The Grays Currency The Grays Currency +15.46%
#10 Wrapped Pulse Wrapped Pulse +15.27%
Coin of the day
Siren Siren
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Synthetic Biologics, Inc. Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

SYN
Classifica tra le azioni #30607
Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on... Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on creating treatments for illnesses with significant unmet medical demands. Among its leading product candidates is SYN-004, engineered to neutralize common intravenous beta-lactam antibiotics within the digestive system. This aims to safeguard the gut microbiome, prevent Clostridium difficile infections (CDI), curb the proliferation of harmful bacteria, combat antimicrobial resistance (AMR), and mitigate acute graft-versus-host-disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key asset is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, intended to address both localized gastrointestinal and systemic conditions. The company is also advancing VCN-01, a therapeutic candidate for various cancers, including pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Additional clinical-stage programs include SYN-006, targeting the prevention of aGVHD and infections from carbapenem-resistant enterococci; SYN-007, designed to avert antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for the prevention and treatment of whooping cough (pertussis); and VCN-11, another cancer therapeutic. Synthetic Biologics maintains partnerships with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis supports a Phase 1b/2a clinical trial for SYN-004. The company's main operations are based in Rockville, Maryland.
Prezzo delle azioni
$1.02
Ultima sincronizzazione: 2022-10-13
Capitalizzazione di mercato
$16.16M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Synthetic Biologics, Inc. (SYN)

Categoria

Healthcare
Utile per Synthetic Biologics, Inc. (SYN)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Synthetic Biologics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Synthetic Biologics, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE